Eliquis from Bristol Myers Squibb Co. - oral anticoagulant that reshaped stroke prevention
28.06.2026 - 03:37:27 | ad-hoc-news.de
Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 03:37. Details in the imprint.
The Eliquis tablet lies small and smooth in the palm, a quiet daily ritual for millions trying to keep blood clots at bay. One sip of water, one swallow, and a therapy decision made by cardiologist Dr. Robert L. Gammon years earlier continues to work in the background.
What Eliquis is built for
Eliquis is an oral anticoagulant with the active ingredient apixaban, designed to reduce blood clot formation by selectively inhibiting factor Xa in the coagulation cascade. It is approved to lower the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Beyond atrial fibrillation, Eliquis is indicated for the treatment of deep vein thrombosis and pulmonary embolism, and for reducing the risk of recurrent DVT and PE following initial therapy. It is also used for the prevention of venous thromboembolic events after elective hip or knee replacement surgery in adults.
How it fits into everyday life
For many patients, the biggest contrast to older anticoagulants is practical: Eliquis tablets are taken in fixed doses, without the routine INR blood checks and diet juggling that once defined warfarin therapy. That gives people like long-time patient Maria Sanchez a more self-assured grip on their daily schedule.
The medicine is usually taken twice daily, often at breakfast and dinner, becoming as habitual as brushing teeth. The tablet coating feels smooth on the tongue, and the lack of constant dosage adjustments helps reduce the low-level anxiety some patients described when they lived with variable warfarin dosing.
Background on Bristol Myers Squibb shares
Eliquis sits at the core of Bristol Myers Squibb's cardiovascular portfolio and remains a key pillar of the group's long-term earnings story for holders of Bristol Myers Squibb shares.
Dosing, strengths and safety
Eliquis is available in several tablet strengths, commonly 2.5 mg and 5 mg, with the 5 mg twice-daily dose standard for many adults with non-valvular atrial fibrillation. In patients with certain characteristics, such as older age or low body weight, dose reduction to 2.5 mg twice daily can apply.
Like all anticoagulants, Eliquis carries a real risk of bleeding, from nosebleeds to gastrointestinal bleeding and in rare cases intracranial hemorrhage. That is why clinicians like Professor Michael D. Ezekowitz weigh stroke risk scores against bleeding scores before prescribing and reassess the balance regularly.
What patients notice and what they do not
Most users do not feel Eliquis working directly; there is no obvious sensation of thinner blood or lighter limbs. The experience is more about an absence: fewer hospital appointments for INR checks and fewer worries when eating leafy vegetables or drinking the occasional glass of wine.
On the other hand, bruises can appear a bit more quickly after minor bumps, and cuts may take longer to stop bleeding. Pharmacists routinely remind new users like retiree James Hall to report any unexpected bleeding, black stools or prolonged nosebleeds promptly, and to carry an anticoagulant card when traveling.
Where Eliquis stands in therapy choices
In many guidelines, apixaban is one of several direct oral anticoagulants recommended over vitamin K antagonists for suitable patients with non-valvular atrial fibrillation. The balance of efficacy and bleeding risk has led hospitals from New York to Berlin to include Eliquis on their standard formularies.
Health systems also look hard at cost. Payers and hospital pharmacists weigh the higher acquisition price of Eliquis against the potential savings from fewer strokes, fewer monitoring visits and shorter hospital stays after orthopedic surgery, where clot prevention is critical.
Market reach and availability
Eliquis is co-marketed globally by Bristol Myers Squibb and Pfizer and is available on prescription in North America, Europe and many Asia-Pacific markets. In Germany and other EU countries, reimbursement generally depends on national health insurance decisions and individual contracts.
The product is not a typical over-the-counter item on amazon.de; instead, it flows through pharmacies and hospital channels under strict prescription control. That keeps direct-to-consumer marketing subdued, with the focus on physician education and guideline inclusion rather than glossy consumer campaigns.
Company context and shares
For Bristol Myers Squibb, Eliquis remains one of the most important long-running products in its cardiovascular and thrombosis portfolio, alongside newer oncology and immunology therapies. Overall, the Bristol Myers Squibb share price is tied to how consistently medicines like Eliquis continue to support long-term revenue on the New York Stock Exchange.
Key facts on Eliquis
- Product: Eliquis (apixaban) oral tablets
- Manufacturer: Bristol-Myers Squibb Company
- Category: Classic/Longseller cardiovascular anticoagulant
- Launch: First approvals in the early 2010s, with subsequent expansion to multiple indications and regions
- RRP / Price: Prescription pricing varies by market and reimbursement agreements; typically reimbursed in many health systems rather than paid fully out of pocket
- Availability: Prescription only via pharmacies and hospital channels in major markets including the US and EU
- Target group: Adults with non-valvular atrial fibrillation, patients with DVT or PE, and adults undergoing elective hip or knee replacement at risk for venous thromboembolism
- Highlight / USP: Fixed-dose oral factor Xa inhibitor that eliminates routine INR monitoring for many patients while providing robust stroke and clot prevention in approved indications
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
